The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumInsights - We’re buying AIMT under $14/share range. AIMT’s Palforzia is the first approved treatment for patients with peanut allergies. This is a name that Nestle owns … Continue Reading
PremiumInsights - AC Immune announced that the company received a second milestone payment of CHF10M (swiss franc) from partner Eli Lilly.  This milestone was related to development of ACI-3024, … Continue Reading
Read nowInsights - Bellus (BLU) is up over 10% this morning on news that Merck’s Phase 3 candidate gefapixant met efficacy endpoints in chronic cough (read here). Merck … Continue Reading
Read nowInsights - We think there are some solid value plays with the current market rout. We’re looking at companies with enough cash to weather the storm and … Continue Reading
PremiumInsights - Fennec announced that the US Patent & Trademark Office will issue U.S. Patent 10,596,190 to Pedmark. The patent is titled “Method for Reducing Ototoxicity in Pediatric Patients … Continue Reading
Read nowInsights - Stemline’s FDA approved product is targeting a newly classified ultra-orphan indication called BPDCN. There is no other approved products in this indication. The company is … Continue Reading
PremiumInterviews - PropThink interviewed Dr. CJ Barnum to get his insights on the current state of Alzheimer’s and the neuro-inflammation approach, one of the emerging research strategies. … Continue Reading
Read now
